Cutting-edge diagnostics tests covering multiple aspects of tumors (DNA, RNA, IHC, others) for solid & liquid biopsies
An up to date, comprehensive and proprietary database, OncoKDO, including genomics, drugs, clinical trials and scientific literature
An industry-leading bio-IT SaaS integration & interpretation platform for health care professionals
Effective access to our specialised oncology resources (scientific/genomic, clinical and outcomes data experts) and oncologists network.
A tailored and easy to access Digital platform combining testing and digital patient/HCP data collection.
"Aiding physicians to identify HRAS and other mutations in HNSCC is an essential element of Kura’s clinical development strategy. Streamlining screening processes facilitates timely access to important medical information that could help oncologists and their patients in making treatment decisions"
The study met its predefined success criteria and has been amended to continue enrolling HRAS mutant HNSCC pts, as well as pts with SCC, other than HNSCC, with HRAS mutations into a new Cohort 3. (ESMO 22 october 2018)